The SomaLogic test is designed to measure changes in the levels of 5,000 proteins in blood. Credit: Alden Chadwick.

The Leeds Centre for Personalised Medicine and Health in the UK has launched a clinical trial to investigate the use of a blood protein test in detecting the risk of disease.

Developed by US-based biotech SomaLogic, the test is based on proteomics and is said to indicate an individual’s real-time health status.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The test is designed to measure changes in the levels of 5,000 proteins in blood in order to calculate the risk of a person developing certain disorders, including diabetes and heart disease.

“The researchers will use personalised health insights derived from the blood test to advise people on lifestyle changes in order to help prevent the onset of type 2 diabetes.”

It is based on SomaLogic platform, which delivers insights that allow biomarker discovery, diagnostics development, pharmaceutical discovery and development, and health management.

During the current trial, Leeds researchers will use personalised health insights derived from the blood test to advise people on lifestyle changes in order to help prevent the onset of type 2 diabetes.

The cost of diabetes to the NHS in the UK is said to be over £1.5m an hour which is around 10% of the NHS budget for England and Wales.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, the trial will assess the test’s effectiveness. The trial will be expanded to other clinical sites based on the findings at the Leeds Centre.

Leeds Centre for Personalised Medicine and Health head Dr Michael Messenger said: “Personalised medicine lets us take a deeper look at each person’s individual biology so we can better understand what the right advice or treatment, at the right time, might be for that person.

“Advances in science, medicine and new technologies, such as this test, help us do exactly that, which is great news for patients and their families. The test results will mean GPs can discuss with those patients lifestyle changes they could make to help them avoid the onset of diabetes, for example, helping them live healthier lives for longer.”

At present, Leeds Centre for Personalised Medicine and Health has formed multiple alliances, including with NHS Leeds Clinical Commissioning Group and local GPs, to enrol 1,000 patients from up to 24 general practices.

Additional reporting by Charlotte Edwards.